Effect of nalidixic acid and hydroxyurea on division ability of Escherichia coli fil+ and lon- strains.
Short periods of incubation in medium containing nalidixic acid or hydroxyurea, followed by a return to normal growth conditions, induced filament formation in Escherichia coli B (fil(+)) and AB1899NM (lon(-)) but not in B/r (fil(-)) and AB1157 (lon(+)). These drugs reversibly stopped deoxyribonucleic acid (DNA) synthesis with little or no effect on ribonucleic acid (RNA) synthesis or mass increase. The initial imbalance caused by incubation in these drugs was the same for B and B/r as was macromolecular synthesis following a return to normal growth conditions. DNA degradation caused by nalidixic acid was measured and found to be the same for B and B/r. Hydroxyurea caused no DNA degradation in these two strains. Survival curves as determined under various conditions by colony formation suggested that the property of filament formation was responsible for the extrasensitivity of fil(+) and lon(-) strains to either nalidixic acid or hydroxyurea. E. coli B was more sensitive to either drug than was B/r or B(s-1). Pantoyl lactone or liquid holding treatment aided division and colony formation of nalidixic acid-treated B but had no effect on B/r. Likewise, the filament-former AB1899NM was more sensitive to nalidixic acid than was the non-filament-former AB1157. The sensitivity of B/r and B(s-1) to nalidixic acid was nearly the same except at longer times in nalidixic acid, when B(s-1) appeared more resistant. Even though nalidixic acid, hydroxyurea, and ultraviolet light may produce quite different molecular alterations in E. coli, they all cause a metabolic imbalance resulting in a lowered ratio of DNA to RNA and protein. We propose that it is this imbalance per se rather than any specific primary chemical or photochemical alterations which leads to filament formation by some genetically susceptible bacterial strains such as lon(-) and fil(+).
D001426:Bacterial Proteins / Q000096:biosynthesis; D002247:Carbon Isotopes; D002455:Cell Division / Q000187:drug effects*; D004261:DNA Replication / Q000187:drug effects; D004269:DNA, Bacterial / Q000378:metabolism; D004926:Escherichia coli / Q000166:cytology / Q000187:drug effects*; D006918:Hydroxyurea / Q000494:pharmacology*; D007783:Lactones / Q000494:pharmacology; D009268:Nalidixic Acid / Q000494:pharmacology*; D012329:RNA, Bacterial / Q000096:biosynthesis; D013936:Thymidine / Q000378:metabolism; D014316:Tritium; D014498:Uracil / Q000378:metabolism
D001426:Bacterial Proteins; D002247:Carbon Isotopes; D004269:DNA, Bacterial; D007783:Lactones; D012329:RNA, Bacterial; D014316:Tritium; D009268:Nalidixic Acid; D014498:Uracil; D013936:Thymidine; D006918:Hydroxyurea